Oruka Therapeutics, Inc. (NASDAQ: ORKA) is a clinical-stage biotechnology company developing novel biologics for chronic skin diseases, and its news flow reflects the progress of a focused dermatology pipeline. Company press releases highlight advances for its lead monoclonal antibodies ORKA-001 and ORKA-002, both engineered to target key immunology pathways in plaque psoriasis and related conditions while enabling infrequent dosing.
News updates frequently cover clinical milestones such as Phase 1 interim data, initiation and enrollment of Phase 2 trials, and detailed designs of the EVERLAST-A and EVERLAST-B studies of ORKA-001 in moderate-to-severe plaque psoriasis. Oruka also reports on the first-in-human trial of ORKA-002, including pharmacokinetic and pharmacodynamic findings that support potential twice-yearly dosing in psoriasis and quarterly dosing in hidradenitis suppurativa.
In addition to pipeline developments, Oruka’s news includes quarterly financial results, corporate updates, and capital-raising activities, such as a private placement financing described in company communications. Governance and leadership items, including board appointments and executive promotions, are disclosed through both press releases and Form 8-K filings. The company also announces participation in major healthcare and investor conferences, where it presents clinical data and corporate overviews.
Investors and observers following ORKA news can expect coverage of clinical trial data readouts, regulatory milestones such as IND clearance, financing transactions, and changes in leadership or board composition. This page aggregates those updates so readers can monitor how Oruka’s psoriatic disease programs and broader antibody portfolio evolve over time.
Oruka Therapeutics (ORKA) reported positive Week 28 data from the EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe plaque psoriasis.
Among patients initially randomized to ORKA-001, PASI 100 response rates increased from 63.5% at Week 16 to 71.4% (45/63) at Week 28, and PASI 90 rose to 87.3% (55/63), six months after the last dose at Week 4. IGA 0/1 responses were maintained at 84.1% (53/63). Patients who started on placebo and crossed over to ORKA-001 at Week 16 achieved PASI 100 in 40.0% (8/20) by Week 28, similar to the 42.9% (27/63) rate in the active arm at the same timepoint post‑dosing.
Between Weeks 16–28, upper respiratory tract infection was the only treatment-emergent adverse event occurring in ≥5% of patients, seen in 8% (7/83). Two serious adverse events were reported, neither considered drug related, and there were no injection site reactions. Oruka expects 52‑week EVERLAST-A data in December 2026 and 16‑week EVERLAST-B Phase 2b data in 4Q 2026.
Oruka Therapeutics (ORKA) will attend the 2026 Morgan Stanley Global Healthcare Conference in New York, NY, taking place from September 14-16, 2026.
Oruka is a clinical-stage biotechnology company developing novel biologics for chronic skin diseases, including plaque psoriasis and hidradenitis suppurativa.
Oruka Therapeutics (Nasdaq: ORKA) announced the appointment of Todd Edwards as Chief Commercial Officer, effective August 24, 2026. Edwards brings over 25 years of commercial leadership experience in immunology and dermatology across biologic and topical therapies, most recently serving as Executive Vice President and Chief Commercial Officer at Arcutis Biotherapeutics.
According to Oruka, Edwards previously built a dermatology business unit at Incyte and led major immunology franchises at UCB, following senior roles at AbbVie and TAP Pharmaceuticals. His appointment aligns with Oruka’s plans to advance its biologic candidates ORKA-001 and ORKA-002 toward potential commercialization in chronic skin diseases.
Oruka Therapeutics (Nasdaq: ORKA) reported second quarter 2026 results and detailed progress across its dermatology pipeline. EVERLAST-A, a Phase 2a trial of IL-23p19 antibody ORKA-001 in plaque psoriasis, previously showed PASI 100 at Week 16 in 63.5% (40/63) of treated participants, with PASI 90 in 83% and IGA 0/1 in 84%, and was well tolerated. Week 28 data are expected at the end of 3Q 2026 and 52‑week data in December 2026. EVERLAST-B, a 187‑subject Phase 2b study, completed enrollment, with Week 16 data expected in 4Q 2026 and a Phase 3 program targeted for 1H 2027.
For ORKA-002 (IL‑17A/F antibody), Week 16 data from ORCA-SURGE are now expected in 1Q 2027, and Phase 2 HS trial ORCA-SPLASH has been initiated in ~160 patients. Oruka introduced ORKA‑004, a TL1A antibody slated for clinic entry in 4Q 2026 and planned 2027 combination Phase 2 studies. Cash, cash equivalents and marketable securities totaled $1.1 billion at June 30, 2026, supported by an upsized $700 million April 2026 offering, which are expected to fund operations through an anticipated BLA filing for ORKA‑001 and continued ORKA‑002 development.
Oruka Therapeutics (Nasdaq: ORKA), a clinical-stage biotechnology company focused on chronic skin diseases such as plaque psoriasis, will present at the 2026 Jefferies Global Healthcare Conference in New York from June 2-4, 2026.
Oruka’s presentation is scheduled for June 3, 2026 at 3:45 PM ET, with a webcast and replay available on its investor events website.
Oruka Therapeutics (Nasdaq: ORKA) reported first quarter 2026 results and clinical, financing, and partnering updates.
ORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100, strong PASI 90/IGA responses, and tolerability similar to placebo, with PK/PD supporting potential annual dosing. ORKA-002 advanced into Phase 2 psoriasis with HS Phase 2 planned for 2H 2026. A $700 million upsized public offering and a Halozyme Hypercon collaboration are expected to fund operations through an anticipated BLA for ORKA-001 and continued ORKA-002 development. Cash, cash equivalents and marketable securities were $496.0 million; Q1 2026 net loss was $31.8 million.
Halozyme (Nasdaq: HALO) and Oruka (Nasdaq: ORKA) entered a global exclusive collaboration and license agreement dated May 6, 2026, granting Oruka rights to Halozyme's Hypercon™ microparticle technology for ORKA-001 (psoriasis) and an option for one additional target.
Terms include an upfront payment, potential future milestone payments, and mid-single digit royalties to Halozyme on net sales of Hypercon-enabled products.
Oruka Therapeutics (Nasdaq: ORKA) priced an upsized underwritten public offering of 9,660,000 common shares at $72.50 per share, expected to raise approximately $700.4 million in gross proceeds before underwriting discounts, commissions and offering expenses.
The company granted underwriters a 30‑day option to purchase up to an additional 1,449,000 shares. The offering is expected to close on or about April 30, 2026, subject to customary closing conditions. A shelf registration on Form S‑3 became effective on April 10, 2026.
Oruka Therapeutics (Nasdaq: ORKA) announced a proposed underwritten public offering of $500 million of common stock and, for certain investors, pre-funded warrants, with a 30-day underwriter option to purchase up to an additional $75 million. The offering is subject to market and other conditions and may not be completed.
Joint bookrunners include Leerink Partners, TD Cowen, Goldman Sachs, Stifel and Guggenheim; a Form S-3 shelf registration became effective April 10, 2026.
Oruka Therapeutics (NASDAQ: ORKA) reported positive interim EVERLAST-A Phase 2a results for ORKA-001 in moderate-to-severe plaque psoriasis. At Week 16, 63.5% (40/63) achieved PASI 100; PASI 90 83%; IGA 0/1 84%. Safety was comparable to placebo with no serious TEAEs; TEAE rates were 51% (ORKA-001) vs 57% (placebo). Updated Phase 1 PK/PD data showed concentrations above effective trough levels for a year, supporting potential annual dosing. Longer-term Week 28 and 52 follow-up data expected in 2H 2026; Phase 2b EVERLAST-B data expected in 2027. Webcast held April 27, 2026 at 8:00 a.m. ET.